The Japanese Pharmaceutical Industry
Its Evolution and Current Challenges
Seiten
2018
Routledge (Verlag)
978-1-138-48143-5 (ISBN)
Routledge (Verlag)
978-1-138-48143-5 (ISBN)
- Titel z.Zt. nicht lieferbar
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Charting the development of the industry from post-war devastation, through good recovery in the 1960s, and then up to the present, the book explores why Japan, despite being a world leader in many high technology industries, is only a minor player in the global pharmaceutical industry.
This book explores why Japan, despite being a world leader in many high technology industries such as automobiles and consumer electronics, is only a minor player in the global pharmaceutical industry. Japan provides a huge market for pharmaceuticals as the second largest consumer of prescription drugs after the United States, and is a massive importer of prescription drugs, relying on discoveries made elsewhere. This book charts the development of the industry, from the devastation resulting from the Second World War to its performance in the present day. Focusing in particular on antibiotics and anticancer drugs, the book analyses factors that have prevented Japan from leading the rapid advances in science and technology that have occurred globally over recent decades. Looking at the pharmaceutical industry, the book argues that the Japanese government’s research and development policies were not sufficiently incentivising. It also shows how the nature of capitalism in Japan - which featured close relations between government and industry as well as between and within firms - was appropriate for nurturing industrial development in the immediate post-war decades, but became much less effective in later years.
This book explores why Japan, despite being a world leader in many high technology industries such as automobiles and consumer electronics, is only a minor player in the global pharmaceutical industry. Japan provides a huge market for pharmaceuticals as the second largest consumer of prescription drugs after the United States, and is a massive importer of prescription drugs, relying on discoveries made elsewhere. This book charts the development of the industry, from the devastation resulting from the Second World War to its performance in the present day. Focusing in particular on antibiotics and anticancer drugs, the book analyses factors that have prevented Japan from leading the rapid advances in science and technology that have occurred globally over recent decades. Looking at the pharmaceutical industry, the book argues that the Japanese government’s research and development policies were not sufficiently incentivising. It also shows how the nature of capitalism in Japan - which featured close relations between government and industry as well as between and within firms - was appropriate for nurturing industrial development in the immediate post-war decades, but became much less effective in later years.
Maki Umemura is a lecturer in Japanese studies at Cardiff Business School, Cardiff University, UK.
1. Introduction: Why didn’t Japan become a global leader in pharmaceuticals? 2. A historical overview of Japan’s pharmaceutical industry 3. Developing a modern industry: The antibiotics sector 4. What went wrong? The anticancer drug sector 5. Conclusion: Reconsidering Japan’s business in pharmaceuticals
| Erscheinungsdatum | 14.07.2018 |
|---|---|
| Reihe/Serie | Routledge Studies in the Growth Economies of Asia |
| Zusatzinfo | 7 Tables, black and white; 18 Line drawings, black and white; 18 Illustrations, black and white |
| Verlagsort | London |
| Sprache | englisch |
| Maße | 156 x 234 mm |
| Gewicht | 380 g |
| Themenwelt | Medizin / Pharmazie ► Pharmazie |
| Naturwissenschaften ► Biologie | |
| Sozialwissenschaften ► Soziologie ► Spezielle Soziologien | |
| Technik | |
| Wirtschaft ► Volkswirtschaftslehre | |
| ISBN-10 | 1-138-48143-2 / 1138481432 |
| ISBN-13 | 978-1-138-48143-5 / 9781138481435 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
eine Einführung
Buch | Softcover (2024)
De Gruyter Oldenbourg (Verlag)
CHF 41,90
